NCT07023432View on ClinicalTrials.gov

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 3, 2025

Primary Completion Date

April 14, 2028

Study Completion Date

April 14, 2030

Conditions
Active SurveillanceClear Cell Renal Cell Carcinoma
Interventions
DRUG

Belzutifan

Given by PO

OTHER

Active Surveillance

Given by Observation

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER